The Perinatal Stem Cell Society has partnered with PRESENT e-Learning Systems to bring you the Future of Regenerative Medicine Congress: Extending and Improving lives with Perinatal, Adipose and Bone Marrow Stem Cells. This International Congress will take place May 19th-21st in Teaneck, NJ in 2017.
This 3-day event will feature the world’s leading perinatal stem cell researchers, specializing in developing therapeutics from Amnion, Amniotic fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. We will also bring the leading surgeons and front line stem cell practicianers to the stage so that they can share with the audience their own intimate experience about what has worked best to produce position patient outcomes. Our goal for this meeting is to acknowledge that there are many types of stem cell treatments taking place in the US and to guide clinicians on the very best methods available. We will have talks on Allograft products from Perinatal Tissues, talks on Adipose processing methods and results from these type of stem cell treatments in the clinic as well as bone marrow and PRP. Our goal is to help advance the field so that the best outcomes are made available to patients. We also will include talks that look toward the future of the field and where we believe the field of regenerative medicine is headed.
Anthony Atala, MD
Director, Wake Forest Institute for Regenerative Medicine, H. Boyce Professor and Chair of Urology, Wake Forest School of Medicine Professor. Dr. Atala is a practicing surgeon and a researcher in the area of regenerative medicine. His work focuses on growing human cells, tissues and organs.
Dr. Atala works with several journals and serves in various roles, including Editor-in-Chief of: Stem Cells- Translational Medicine; Current Stem Cell Research and Therapy; Therapeutic Advances in Urology; and BioPrinting. Dr. Atala is a recipient of awards, including the US Congress funded Christopher Columbus Foundation Award, bestowed on a living American who is currently working on a discovery that will significantly affect society, the World Technology Award in Health and Medicine, the Samuel D. Gross Prize in Surgical Research, the Innovation Award from the Society of Manufacturing Engineers, the Rocovich Gold Medal, and the Edison Science/Medical Award for work in 3D Bioprinting. In 2011 he was elected to the Institute of Medicine of the National Academy of Sciences, and in 2014 was inducted to the National Academy of Inventors as a Charter Fellow. Dr. Atala’s ongoing work has been described in the lay press. Dr. Atala’s work was listed in 2007 as Time Magazine’s top 10 medical breakthroughs of the year, by Discover Magazine in 2007 as the Number 1 Top Science Story of the Year in the field of medicine, by Smithsonian Magazine in 2010 as one of 40 things to know about the next 40 years, by Time Magazine in 2011 as one of the top 5 medical breakthroughs of the year, by the Huffington post in 2011 as one of 18 great ideas for the future, and by Time Magazine in 2013 as one of 5 discoveries that will change the future of organ transplants.
Dr. Atala was named by Scientific American in 2010 as a Medical Treatments Leader of the Year for his contributions to the fields of cell, tissue and organ regeneration, by U.S. News & World Report in 2009 in as one of 14 Pioneers of Medical Progress in the 21st Century, by the American Association of Retired Persons in 2012 as one of the 50 influential people who will make life better, and by Scientific American in 2015 as one of the world’s most influential people in biotechnology. Dr. Atala has led or served several national professional and government committees, including the National Institutes of Health working group on Cells and Developmental Biology, the Bioengineering Consortium, the National Cancer Institute’s National Cancer Advisory Board, and was the Founder of the Regenerative Medicine Foundation. Dr. Atala heads a team of over 450 physicians and researchers. Over twelve applications of technologies developed in Dr. Atala’s laboratory have been used clinically. He is the editor of fourteen books, including Principles of Regenerative Medicine, 3D Biofabrication, Essentials of Stem Cell Biology, and Methods of Tissue Engineering. He has published more than 500 journal articles and has applied for or received over 250 national and international patents.
Curtis L. Cetrulo, Jr., MD
Plastic and Reconstructive Surgery, Massachusetts General Hospital
Dr. Cetrulo is a nationally-respected clinical microsurgeon and educator, and a national leader in vascularized composite allotransplantation.
Dr. Cetrulo graduated from Stanford University in 1992 and Tufts University School of Medicine in 1999. Following general surgery residency training, a plastic surgery research fellowship, plastic surgery residency training and hand and microsurgery fellowship training, Dr. Cetrulo practiced reconstructive microsurgery and hand surgery at the University of Southern California Medical Center (USC). He also performed pediatric reconstructive microsurgery, burn reconstruction, cleft lip/palate surgery, and pediatric hand surgery at the Shriners Hospital for Children-Los Angeles from 2007-2009. In addition, Dr. Cetrulo established and directed a translational research laboratory dedicated to composite tissue allograft research. Dr. Cetrulo participated in many medical missions while at USC.
In 2009, Dr. Cetrulo joined the Division of Plastic and Reconstructive Surgery of the Massachusetts General Hospital (MGH) and the Massachusetts General Hospital for Children, as well as the staff of Shriners Hospital for Children-Boston. Dr. Cetrulo’s surgical practice is dedicated to preforming cutting–edge complex adult and pediatric reconstructive microsurgery, as well as to hand surgery, breast reconstruction, and burn reconstruction. Dr. Cetrulo has published numerous clinical research contributions to the microsurgery literature.
Dr. Cetrulo established of the first Vascularized Composite Allotransplantation Service at MGH, from inception to regulatory board approval to performance of MGH’s first hand transplantation. Dr. Cetrulo’s hand transplant case has been distinguished by the patient’s superior functional outcome compared to other hand transplant recipients throughout the world, as well as for widening the applicability of this procedure for burned amputees.
Dr. Cetrulo also serves as the Senior Investigator and Head of the Vascularized Composite Tissue Allotransplantation Laboratory at the Transplantation Biology Research Center, Massachusetts General Hospital. The TBRC laboratory is investigating tolerance induction strategies for vascularized composite tissue allografts (VCA) in the immunogenetically-defined MGH miniature swine model as well as in non-human primate models. Current research efforts are directed toward use of mixed hematopoietic chimerism to induce transplantation tolerance to VCA and toward exploring the immunologic mechanisms involved in tolerance and rejection of the skin component of VCA. TBRC recently published an important contribution to the field: the first demonstration of immunologic tolerance of all components of a VCA in a large animal, preclinical model.
Adam William Anz, M.D. is an Orthopaedic surgeon who is fellowship trained in sports related injuries focusing on knee surgery, hip arthroscopy, and orthobiologics. He has many peer-reviewed publications and presentations with a special interest in cartilage regeneration.
His main goals are to keep patients as active as possible in the least invasive way and constantly improve our Orthopaedic techniques. Dr. Anz graduated summa cum laude from Vanderbilt University with a degree in mathematics and Alpha Omega Alpha from the University of South Alabama College of Medicine. His orthopaedic surgery residency training was at Wake Forest University in Winston- Salem, North Carolina, and he completed a sports fellowship at the Steadman Clinic in Vail, Colorado where he learned complex knee surgery from Drs. Steadman and Laprade and hip arthroscopy from Dr. Philippon. Dr. Anz has numerous Othopaedic journal publications and a strongest interest in biologic augmentation of our current surgical techniques. In 2009, he first visited with Dr. Khay Yong Saw in Kuala Lumpur, Malaysia, who has pioneered a method to regenerate cartilage using a patients own stem cells, and has returned for a total of four visits to collaborate with Dr. Saw. Currently, Drs. Saw and Anz are initiating a multicenter trial involving this cell technology to advance its status with the US FDA. Additional current projects include biomechanical strength testing of new arthroscopic suture techniques, repair of the biceps femoris, and synovial stem cell augmentation of ACL reconstruction.